Skip to main content
Premium Trial:

Request an Annual Quote

Amos Goren , Philip Young, Frank Witney, Gary Madsen, Brian Lightbody

Premium

Tel Aviv, Israel-based Compugen said last week that Amos Goren and Philip Young left its board of directors and that Eli Mintz will not stand for re-election to the board.

Frank Witney has become CEO of microarray startup GenoSpectra in Fremont, Calif., joining the company from PerkinElmer Life Sciences, where he was president. Prior to that, he served as president and chief operating officer of Packard BioScience. Previously, he was group operations manager of the life science group at Bio-Rad Laboratories. Witney holds a doctorate in molecular and cell biology from Indiana University.

EraGen Biosciences has appointed Gary Madsen as chief technical officer. As CTO, Madsen will help guide the company's technology development in the areas of nucleic acid diagnostics, functional proteomics and drug innovation. Madsen joins Madison, Wis.-based EraGen from IDEXX Laboratories, where he served as divisional vice president of research and development. In addition, Madsen worked at Abbott Laboratories, where he served as a senior manager and led teams developing diagnostics for AIDS and hepatitis.

Brian Lightbody has joined Bedford, Mass.-based Arradial as vice president of business development. Prior to joining the company, which is developing a microfluidics-based drug discovery platform, Lightbody served as vice president for drug discovery business development at Zymark. Since 1997, Lightbody has also served as chairman for the International Symposium for Laboratory Automation and Robotics.

 

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.